Haemonetics HAE Plasma — Costs incurred, net of reversals

Other segment segments

Similar metrics at other companies

OTT

OTTRNet Periodic Defined Benefits Expense Reversal Of Expense Excluding Service Cost Component

-$443K+65.4%

CSXNet Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component

-$8.25M+34.0%

GHC

GHCNet Periodic Defined Benefits Expense Reversal Of Expense Excluding Service Cost Component

-$31.07M+10.2%

SONNet Periodic Defined Benefits Expense Reversal Of Expense Excluding Service Cost Component

$2.5M-20.0%

OLNNet Periodic Defined Benefits Expense Reversal Of Expense Excluding Service Cost Component

-$3.5M+38.6%

CZRTransaction and other costs, net

$4M+100%

Questions, answered.

What is Haemonetics's plasma — costs incurred, net of reversals?

Haemonetics (HAE) reported plasma — costs incurred, net of reversals of $0 in Q1 2026.

What is the long-term trend for Haemonetics's plasma — costs incurred, net of reversals?

Over 2 years (2022 to 2026), Haemonetics's plasma — costs incurred, net of reversals has grown at a -57.7% compound annual growth rate (CAGR), from $2.51M to $448K.

What does plasma — costs incurred, net of reversals mean?

Represents the net expenses recognized by the plasma business segment after accounting for any reversals of previously accrued costs. This metric reflects the operational impact of specific non-recurring or project-based charges within the segment. It helps investors isolate the net financial burden of specific initiatives or adjustments.